Akari Therapeutics, Plc

NasdaqCM AKTX

Akari Therapeutics, Plc EBIT Margin for the year ending December 31, 2023

Akari Therapeutics, Plc EBIT Margin is NA for the year ending December 31, 2023. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

Key data

Date	EBIT Margin	EPS (Basic)	EPS (Diluted)	Shares (Basic, Weighted)

NasdaqCM: AKTX

Akari Therapeutics, Plc

CEO	Dr. Samir Rashmikant Patel M.D.
IPO Date	Jan. 6, 2014
Location	United Kingdom
Headquarters	75/76 Wimpole Street
Employees	6
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals Vaccines

Description

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

Key trends

Past 5 years